Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

Angiogenesis is the process through which new blood vessels are formed from pre-existing
ones. Exosomes are involved in angiogenesis in cancer progression by transporting …

All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …

Prior to the recent therapeutic advances, chemotherapy was the mainstay of treatment
options for advanced-stage melanoma. A number of studies have investigated various …

Purpose: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein
kinase ataxia telangiectasia and Rad3-related (ATR) protein. Patients and Methods: Eligible …

Cutaneous melanoma is a malignancy arising from melanocytes of the skin. Incidence rates
are rising, particularly in White populations. Cutaneous melanoma is typically driven by …